Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Neuropace, Inc. - Common Stock (NQ:NPCE)

13.75 +0.11 (+0.81%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	229,164
Open	13.69
Bid (Size)	13.50 (100)
Ask (Size)	14.26 (400)
Prev. Close	13.64
Today's Range	13.51 - 14.11
52wk Range	7.562 - 19.60
Shares Outstanding	24,296,259
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

NeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More Data ↗

July 28, 2026

NeuroPace (NASDAQ:NPCE) said the U.S. Food and Drug Administration determined that its premarket approval supplement seeking to expand the RNS System indication to patients with medication-resistant...

Via MarketBeat

These stocks are moving in today's after hours session ↗

July 28, 2026

Via Chartmill

Performance

YTD	-9.4%	-9.4%
1 Month	-16.8%	-16.8%
3 Month	-16.9%	-16.9%
6 Month	-11.9%	-11.9%
1 Year	+56.6%	+56.6%

More News

NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy

July 28, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting

May 29, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace (NASDAQ:NPCE) Beats Q1 Estimates, Raises Full-Year Revenue Guidance ↗

May 12, 2026

Via Chartmill

NeuroPace Inc (NASDAQ:NPCE) Beats Q4 2025 Estimates and Reiterates 2026 Outlook ↗

March 03, 2026

Via Chartmill

NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care

May 29, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace (NPCE) Q1 2026 Earnings Transcript ↗

May 14, 2026

Via The Motley Fool

NeuroPace Q1 Earnings Call Highlights ↗

May 12, 2026

Via MarketBeat

NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

May 12, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026

April 29, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026

April 27, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference

April 10, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace to Present at the Leerink Global Healthcare Conference

March 05, 2026

From NeuroPace, Inc.

Via Business Wire

Why NeuroPace Stock Was Inching Higher on Wednesday ↗

March 04, 2026

Via The Motley Fool

NeuroPace (NPCE) Q4 2025 Earnings Call Transcript ↗

March 03, 2026

Via The Motley Fool

NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook

March 03, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026

February 20, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

January 13, 2026

From NeuroPace, Inc.

Via Business Wire

NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 31, 2025

From NeuroPace, Inc.

Via Business Wire

NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy

December 17, 2025

From NeuroPace, Inc.

Via Business Wire

NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

December 08, 2025

From NeuroPace, Inc.

Via Business Wire

NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting

December 02, 2025

From NeuroPace, Inc.

Via Business Wire

NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services

November 24, 2025

From NeuroPace, Inc.

Via Business Wire

NeuroPace (NPCE) Q3 2025 Earnings Call Transcript ↗

November 09, 2025

Via The Motley Fool

Frequently Asked Questions

Is Neuropace, Inc. - Common Stock publicly traded?

Yes, Neuropace, Inc. - Common Stock is publicly traded.

What exchange does Neuropace, Inc. - Common Stock trade on?

Neuropace, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Neuropace, Inc. - Common Stock?

The ticker symbol for Neuropace, Inc. - Common Stock is NPCE on the Nasdaq Stock Market

What is the current price of Neuropace, Inc. - Common Stock?

The current price of Neuropace, Inc. - Common Stock is 13.75

When was Neuropace, Inc. - Common Stock last traded?

The last trade of Neuropace, Inc. - Common Stock was at 07/30/26 04:00 PM ET

What is the market capitalization of Neuropace, Inc. - Common Stock?

The market capitalization of Neuropace, Inc. - Common Stock is 334.07M

How many shares of Neuropace, Inc. - Common Stock are outstanding?

Neuropace, Inc. - Common Stock has 334M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.